HOMEGROWN drug developer S*Bio has just struck the biggest deal yet since the biomedical sciences push here kicked off in 2000.

It is the first biomed company to strike a licensing deal with a leading drug company.

Under the recently inked deal, S*Bio, which is Singapore's first research and development (R&D) biomed company, has received US$25 million from US-based Onyx Pharmaceuticals to develop two of S*Bio's potential drugs for a type of blood disorders.

For more The Straits Times stories, click here.